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Background Several measures using prescription data have been developed for estimating medication refill adherence. Few studies have
made direct comparisons, and little is known about the accuracy of these measures in patients on a multiple-drug regimen.
Purpose To compare different calculation methods using prescription data for assessing refill adherence.
Method An observational cohort study among type 2 diabetes patients was conducted. Adherence to oral glucose-lowering, antihyper-
tensive and lipid-lowering medication was assessed for 2004. We calculated medication possession ratios in a flexible period (MPRF), per
calendar year (MPRY) and gaps between refills (GAP) at drug class and therapeutic level. Individual review of drug prescription profiles was
conducted to validate identified cases of suboptimal refill adherence. Differences in Area Under the Curve (AUC) of ROC-curves were
calculated to compare the methods.
Results Of the 3877 patients, 2969 (77%) patients received oral glucose-lowering medication, 2715 (70%) antihypertensives and 1797
(46%) lipid-lowering medication. Using cutoffs for MPR< 80% and GAP> 30 days, overall rates of suboptimal adherence for these drug
classes were 32, 35 and 23% respectively. AUC for measures calculated at drug class level (range 0.85–0.90) were significantly larger than
those calculated at therapeutic level (0.72–0.90). For oral glucose-regulating medication and antihypertensives, AUCs were largest for the
MPRY and GAP measures (0.87–0.88). For lipid-lowering medication, the AUC was largest for the GAP measure (0.90).
Conclusions Differences between adherence measures were small and favoured calculation on drug class level. For multiple drug use, both
MPRY and GAP were good measures for identifying suboptimal refill adherence. Copyright # 2008 John Wiley & Sons, Ltd.key words—patient compliance; diabetes mellitus type 2; administrative data; primary health care; drug utilization
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Suboptimal medication adherence is a common
problem in clinical practice.1,2 Especially in patients
in need of various chronic preventive drugs, problems
with discontinuation and under use of medication may
lead to suboptimal achievement of therapeutic tar-
gets.1,3,4 Automated databases with prescription refill
data are increasingly being used for identifying patients
with possible medication adherence problems.5–7*Correspondence to: Dr P. Denig, University Medical Centre Groningen,
Sector F, Department of Clinical Pharmacology, PO Box 196, 9700 AD,
Groningen, The Netherlands. E-mail: P. Denig@med.umcg.nl
yThe authors declare that they have no conflict of interest regarding this
work.
Copyright # 2008 John Wiley & Sons, Ltd.For estimating medication refill adherence, different
methods have been proposed, some focusing on the
duration or continuation of drug refills—often called
persistence—and others more on the sufficient amount
or timely refill of medication within a period of
persistence.7,8 The most simple approach is the
anniversary model.8 Patient adherence to medication
is based on refilling one prescription at the end of the
study period. This approach may be adequate for
measuring persistence but fully disregards the amount
of drugs being refilled during the study period.8 In the
minimum-refills model, a patient is considered
adherent with treatment when a specified number of
prescriptions is refilled during the study period.7,8 This
is still a very rough estimate of the drug amount being
160 n. m. vink ET AL.refilled. A better estimate can be achieved by
calculating the medication possession ratio (MPR).5–9
This is based on the proportion (or percentage) of days’
supply obtained during a specific time period or over a
period of refill intervals. This method, however,
disregards the timeliness of refilling.6,8 To take timely
refilling into account, methods based on refill sequence
are needed.6 Using the start and expected end dates of
prescriptions, the medication gaps between refills
(GAP) can be calculated.
There is no consensus about the best approach for
determining refill adherence using prescription
data.5,6,8–10 Different methods may provide comp-
lementary information on refill patterns.9,11 It has been
advocated that one should at least try to assess
adherence in terms of persistence and adequate extent
of refills.8 So far, little attention has been paid to
calculating refill adherence in patients using multiple
drug regimes. Usually, refill adherence is calculated for
individual drugs and sometimes averaged over the
different drugs used by one patient. When adherence is
calculated on individual drug level, no consideration is
given to patients who switch their medication during
the study period.When adherence is calculated on drug
class level (e.g. b-blocking agents) or on therapeutic
level (e.g. antihypertensive medication) switches
between drugs from the same class or for the same
indication are taken into account. Studies on persist-
ence using refill-sequence models often permit
switches between drugs with shared indications.8
The main aim of this study was to identify preferred
measures for assessing suboptimal medication refill
adherence using prescription data. The outcomes of all
measures were tested against a reference method based
on individual, visual review of the prescription refill
patterns. Next, we made the following comparisons:
(1) between different measures based on MPR and
based on GAP, (2) between calculations made on drug
class and on therapeutic level.
METHODS
We conducted an observational cohort study in all 3877
patients diagnosed and managed for type 2 diabetes
mellitus on 1 January 2005 by 38 general practitioners
(GPs) participating in the GIANTT (Groningen
Initiative to ANalyse Type 2 diabetes Treatment)
project.12 These GPs practiced in one region in The
Netherlands. Since all GPs prescribed electronically,
full prescription information is recorded in the
electronic medical records. Patients that had left the
practice before 1-January 2005, and therefore would
have incomplete data, were excluded.Copyright # 2008 John Wiley & Sons, Ltd.Data collection
The following routinely recorded data were extracted
from the GPs’ electronic medical records: age, gender,
date of diagnosis of diabetes mellitus type 2, blood
pressure and laboratory measurements, and all
prescriptions for glucose-lowering medication, anti-
hypertensive medication and lipid-lowering medi-
cation, including prescribed daily doses and total
quantities prescribed. The study was conducted in
conformance to the Dutch guidelines on the use of
medical data for scientific research. For medical record
research of anonymous data, no IRB approval is needed
in The Netherlands.
Measures of refill adherence
The study was set up to compare different commonly
used approaches for calculating medication refill
adherence in patients that may use multiple drugs or
switch between drugs. Refill adherence was assessed
for the year 2004. It was calculated for three types of
medications: oral glucose-lowering medication, anti-
hypertensive medication and lipid-lowering medi-
cation. Included were two MPR measures that assess
the maximum proportion of days a patient could have
taken the medication as prescribed, and the GAP
measure that assesses whether a patient refilled the
medication in time. Both MPR and GAP measures are
used to identify patients that show suboptimal
medication refill adherence using some (arbitrary)
cutoff to divide patients as being adherent or non-
adherent.6,7 The underlying assumption is that a patient
is either under-using or stopped using the medication
when he/she does not refill medication as expected.
Oversupply is truncated at 100%, since these measures
do not address overuse of medication. In case of
overlapping prescriptions, the second prescription is
shifted forward (see Figure 1), clustering prescriptions
at drugs class or therapeutic level (see next section).
This provides a conservative estimate of suboptimal
adherence, since it accepts that the medication may be
taken sequentially.
The measures were defined as follows (see also
Figure 1): Medication possession ratio using a flexible period
(MPRF), i.e. the number of days for which prescribed
medication was available between the last refill in the
observation year and the last refill in the preceding year
(or the first refill in the observation year when there were
no prescriptions in the preceding year) divided by number
of days between these refills, expressed as percentage. By
definition, this method does not include terminal gaps andPharmacoepidemiology and Drug Safety, 2009; 18: 159–165
DOI: 10.1002/pds
1/1/2004 1/1/2005
Rx 1 Rx 2 Rx 3 Rx 4
MRPF measurement
1/1/2004 1/1/2005
Rx 1 Rx 2 Rx 3 Rx 4
GAP 1 GAP 2
GAP measurement
1/1/2004 1/1/2005
Rx 1 Rx 2 Rx 4Rx 3
MPRY measurement
Figure 1. Examples ofMPRF,MPRYandGAP (largest gap between refills) measurements; Rx are prescriptions. After adjusting for overlapping prescriptions,
the bold black lines for the MPRF/MPRY show the days for which prescribed medication was available, whereas the bold black line for the GAP shows the
largest gap
Co
comparing measures for medication refill adherence 161thus disregards persistence. Assessment of adherence
over short time intervals is likely to be imprecise and
could bias the MPR upwards5,6. Patients for whom the
period between the first and last refill was less than
90 days, are therefore assessed as adherent according
to this measure. The percentage of patients for whom
this occurred was 5% for oral glucose-lowering medi-
cation, 3% for antihypertensive medication and 18% for
lipid-lowering medication. Medication possession ratio using a fixed 1-year period
(MPRY), i.e. the numbers of days for which prescribed
medication was available during the observation year
2004 divided by 366 days, for patients already receiving
drugs in the preceding year. This method assesses per-
sistence in addition to adequate extent of refills but—by
definition—does not address refill adherence of initial
users during the observation year. The percentage of such
patients receiving an initial prescription during the obser-
vation year was 18% for oral glucose-lowering medi-
cation, 11% for antihypertensive medication and 34% for
lipid-lowering medication. GAP, i.e. the number of days between the calculated end
date of a prescription and the start date of the following
prescription. By identifying the largest gap, this method
assesses the maximum single-interval period for whichpyright # 2008 John Wiley & Sons, Ltd.there was an insufficient refill of medication. To calculate
the adherence rate, the gap is divided by 366 days,
expressed as percentage, and then subtracted from 100%.
When information about the daily doses or the total
medication quantities were missing, refill adherence
percentages cannot be calculated, and patients were
excluded from the analysis. Percentage of patients with
such incomplete information ranged between 2 and
5%, and were similar for all tested measures.
Drug class and therapeutic level
Medication was classified according to the ATC-
system (Anatomical Therapeutic Chemical Classifi-
cation system). All measures were first calculated on
drug class level, i.e. for oral glucose-lowering medi-
cation this includes biguanides (ATC-codes A10BAþ
A10BD), SU-derivates (A10BBþA10BD02), acar-
bose (A10BF), glitazones (A10BGþA10BD03) and
glinides (A10BX). For antihypertensives, these are
the diuretics (C03þC07BþC07CþC07DþC08Gþ
C09BAþC09DA), beta-blocking agents (C07),Pharmacoepidemiology and Drug Safety, 2009; 18: 159–165
DOI: 10.1002/pds
162 n. m. vink ET AL.calcium-antagonists (C08þC09BB) and RAS-inhibi-
tors (C09). For lipid-lowering medication, these are
statins (C10AA), fibrates (C10AB), bile acid seques-
trans (C10AC), nicotinic acid derivates (C10AD) and
other lipid modifying drugs (C10AX). Furthermore,
we calculated the MPRY and GAP at the higher
therapeutic class level, i.e. glucose-lowering medi-
cation (A10B), antihypertensives (C03þC07þ
C08þC09) and lipid-lowering medication (C10).
The calculation on drug class level accounts for
switches and overlapping refills within these drug
classes, whereas calculation on therapeutic levels also
takes switches between drug classes and overlapping
refills at therapeutic level into account.Reference method
Individual review of refill patterns was used as
reference method to validate the outcomes of the
different measures of calculating medication refill
adherence. All patients with a MPRF or MPRYof less
than 100%, or a GAP greater than 7 days were
reviewed. For each patient, graphs were generated
showing all prescriptions with the periods covered by
each prescription as well as the related measurements
of clinical outcomes, i.e. glycemic, blood pressure and
lipid measurements. These patient profiles were
visually assessed through a step-wise procedure to
eliminate possible misclassifications that were not
considered to represent suboptimal refill adherence,
using a ‘grace’ period of 7 days after the correction for
overlapping refills. Based on a pilot study where three
researchers assessed between 400 and 500 refill
patterns for each of the three therapeutic groups, and
recommendations made by the Dutch Institute for
Rational Drug Use,13 the following criteria for
misclassifications were included:1. sTable 1. Characteristics of study cohort
Number of patients 3877
Coingle prescriptions of 14 days or less for diuretics and
beta-blocking medication. These were not considered to
represent suboptimal refill adherence, since short-term
prescribing of these drugs may occur for alternative, non-
chronic indications;Male sex 45.6%2. eAge, mean (SD) 66.1 year (12.6)
Diabetes duration, median (IQR) 3.0 (1.0–7.0)
HbA1c, mean (SD) 7.2% (1.2)rrors in the recorded dosing scheme, e.g. prescriptions
with a total quantity of 0 or 1, or a gap that can be
compensated by oversupply from the last refill preceding
the measurement calculation;Systolic blood pressure, mean (SD) 147mmHg (18)
Total cholesterol, mean (SD) 5.1mmol/l (1.0)3. sInsulin 15%
Oral glucose-lowering medication 77%witches between drugs for the same therapeutic class
within 7 days. These were defined as adequate refill
adherence;Antihypertensive medication 70%4. c
Lipid-lowering medication 46%
HbA1c¼Glycosylated hemoglobin; SD¼ standard deviation; IQR¼
interquartile range.oncurrent gaps in all prescriptions and risk factor
measurements, indication of a period of incomplete
documentation in the electronic medical record, for
instance due to a hospital admission;pyright # 2008 John Wiley & Sons, Ltd.5. gaps observed in oral glucose regulating medication in
the period shortly after a start with insulin.
Analysis
We did not use fixed cutoffs to define medication refill
adherence but for the descriptive analysis of adherence
rates we used both very strict cutoffs (MPR< 100%
and GAP> 7days) as well as commonly used cutoffs
(MPR< 80% and GAP> 30 days). Adherence rates
were calculated after exclusion of misclassifications,
resulting in so-called validated (overall) adherence
rates. For each measure and drug level, the sensitivity
and specificity were calculated in comparison to the
individual review outcomes. ROC curves were drawn
and Area Under the Curve (AUC) were calculated for
the whole range of cutoffs. To compare and test for
differences in the performance of different measures,
differences of AUC (with 95% confidence interval)
were calculated, using the method of Hanley et al.14
This method compares AUC derived from the same set
of patients by taking into account the correlation
between the areas. We considered AUCs between 0.8
and 0.9 as indicating good performance, and higher
than 0.9 as indicating excellent performance.
RESULTS
Themean age of all patients was 66 years, and 46%were
male (Table 1). Of all patients, 2969 (77%) received oral
glucose-lowering medication, 2715 (70%) received
antihypertensive medication and 1797 (46%) received
lipid-lowering medication in 2004 (Table 1).
Individual review of the refill adherence patterns at
drug class level resulted in 11% misclassifications,
being cases with a calculated incomplete refill of more
than 7 days but fulfilling one of the predefined criteria
for misclassification. After correction for misclassifi-
cations, suboptimal refill adherence was calculated for
various cutoffs used for defining patients’ adherence.Pharmacoepidemiology and Drug Safety, 2009; 18: 159–165
DOI: 10.1002/pds
Table 2. Suboptimal refill adherence rates according to the various measures
Measure and cutoff used Number of patients receiving the following medication
Glucose-lowering N¼ 2756 Antihypertensive N¼ 2502 Lipid-lowering N¼ 1713
Non-adherent Non-adherent Non-adherent
MPRF drug class <80% 462 (17%) 485 (19%) 218 (13%)
MPRY drug class <80% 608 (22%) 556 (22%) 222 (13%)
GAP drug class >30 days 620 (23%) 643 (26%) 305 (18%)
MPRY therapeutic level <80% 383 (14%) 261 (10%) 216 (13%)
GAP therapeutic level >30 days 457 (17%) 339 (14%) 299 (18%)
Validated overall rate 878 (32%) 874 (35%) 387 (23%)
MPRF¼medication possession ratio calculated using a flexible period; MPRY¼medication possession ratio calculated using 1 year; GAP¼ (largest) gap
between refills.
comparing measures for medication refill adherence 163Using the strict criteria of the MPR <100% and the
GAP >7 days, overall suboptimal adherence rates as
validated by the reference method were 58% (1600
patients) for oral glucose-lowering medication, 61%
(1534 patients) for antihypertensive patients and 49%
(832 patients) for lipid-lowering medication. When
using the cutoffs most frequently used in the literature
(MPR <80% and GAP >30 days), the overall rates
validated by the reference method were 32, 35 and
23%, respectively (Table 2).
The ROC curves for all measures at drug class level
showed steep increases, with sensitivities between 60
and 70% at specificities between 95 and 80% for
identifying suboptimal refill adherence as validated by
the reference method (Table 3). For oral glucose-
lowering and antihypertensive medication, the sensi-
tivities were higher for the MPRY and GAP in
comparison to MPRF measure, whereas for lipid-




MPRF drug class <70% 17.8% 99.6%
MPRF drug class <80% 28.9% 99.2%
MPRF drug class <90% 44.8% 98.3%
MPRF drug class <95% 61.6% 95.3%
MPRY drug class <70% 27.1% 97.7%
MPRY drug class <80% 38.0% 97.1%
MPRY drug class <90% 56.4% 95.6%
MPRY drug class <95% 74.4% 91.5%
GAP drug class >7 days 82.4% 86.2%
GAP drug class >15 days 60.6% 94.3%
GAP drug class >30 days 38.8% 97.9%
MPRY therapeutic level <70% 15.8% 99.7%
MPRY therapeutic level <80% 23.9% 99.3%
MPRY therapeutic level <90% 38.4% 97.8%
MPRY therapeutic level <95% 53.5% 95.2%
GAP therapeutic level >7 days 62.8% 88.3%
GAP therapeutic level >15 days 43.2% 95.2%
GAP therapeutic level >30 days 27.2% 98.0%
Copyright # 2008 John Wiley & Sons, Ltd.showed higher sensitivities over a range of cutoffs. For
measures calculated at therapeutic level, the sensi-
tivities were clearly lower in comparison to the drug
class level for both oral glucose-lowering and
antihypertensive medication (Table 3).
AUC for measures calculated at drug class level
(range 0.85–0.90) were significantly larger than those
calculated at therapeutic level (0.72–0.90) (Table 4).
For oral glucose-regulating medication and antihyper-
tensives, AUCs above 0.8 were observed for the MPRY
and GAP measures (0.87–0.88). For lipid-lowering
medication, the AUC was largest for the GAP measure
(0.90) but high AUCs were also observed for theMPRF
and MPRY measures (0.86). Comparing the AUC for
identifying suboptimal refill adherence as validated by
the reference method, the MPRY and GAP measures
were significantly better than the MPRF for oral
glucose-lowering and antihypertensive medication
(Table 4). For lipid-lowering medication, the GAPl adherence
f patients receiving the following medication
Antihypertensive (N¼ 2502) Lipid-lowering (N¼ 1713)
Sensitivity Specificity Sensitivity Specificity
22.5% 99.2% 16.0% 99.7%
31.6% 99.1% 26.2% 99.3%
48.3% 97.7% 44.5% 98.8%
63.6% 94.6% 60.8% 96.5%
25.6% 96.7% 15.7% 99.9%
36.2% 96.5% 26.7% 99.4%
55.9% 94.0% 45.8% 98.8%
74.6% 89.0% 66.2% 94.8%
84.2% 82.7% 85.3% 90.4%
63.2% 92.8% 60.3% 95.2%
41.9% 97.6% 36.6% 98.6%
11.3% 99.5% 15.0% 99.9%
17.0% 99.4% 26.0% 99.4%
30.2% 97.6% 44.8% 98.8%
44.0% 94.4% 64.9% 94.8%
55.5% 87.4% 83.8% 90.5%
37.6% 94.9% 59.3% 95.2%
22.1% 97.8% 35.9% 98.6%
Pharmacoepidemiology and Drug Safety, 2009; 18: 159–165
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Table 4. Comparison of the various measures to the reference method: AUC of ROC curves with standard errors (SE)






MPRF on drug class level 0.847 (0.007) 0.857 (0.008) 0.861 (0.010)
MPRY on drug class level 0.883y (0.007) 0.868y (0.008) 0.858 (0.010)
GAP on drug class level 0.873y (0.007) 0.874y (0.007) 0.904zx (0.008)
MPRY on therapeutic level 0.800k (0.008) 0.727k (0.010) 0.850 (0.010)
GAP on therapeutic level 0.775 (0.009) 0.717 (0.010) 0.895 (0.008)
MPRF¼medication possession ratio calculated using a flexible period; MPRY¼medication possession ratio calculated using 1 year; GAP¼ (largest) gap
between refills; in bold are the largest AUCs for each therapeutic area are given.
AUC for MPRY/GAP significantly higher in comparison to MPRF on drug class level.
yAUC for MRPY/GAP on drug class level significantly higher in comparison to therapeutic level.
zAUC for GAP significantly higher in comparison to MPRF/MPRY on drug class level.
xAUC for GAP on drug class level significantly higher in comparison to therapeutic level.
kAUC for MPRY significantly higher in comparison to GAP on therapeutic level.
AUC for GAP significantly higher in comparison to MPRY on therapeutic level.
164 n. m. vink ET AL.method was significantly better than the measures
based onMPR.Measures calculated on drug class level
were significantly better for all three medication
groups in comparison with measures calculated on
therapeutic level (Table 4).
DISCUSSION
We found that for therapeutic areas where multiple
drug use is common, both the MPRYand calculation of
GAP are suitable measures to identify suboptimal
medication refill adherence. For assessing suboptimal
refill adherence in an area where single drug use is
common, GAP appears to be the most sensitive
method. Furthermore, we observed that measures
calculated on drug class level were significantly better
than measures calculated on therapeutic level.
Previous investigations assessing medication adher-
ence with prescription refill data did not lead to
consensus about the best measure. Adherence has been
defined ambiguously in the literature, which makes it
difficult to draw conclusions about the best measure to
use. Hess et al. concluded that the medication refill
adherence measure, in our study called the MPR, is the
preferred method, because of its simplicity and the fact
that it provides results identical to those achieved with
other continuous measures of medication possession or
GAP.9 Caeteno et al. concluded that the best measure
for assessing adherence problems was the use of a
hybrid model, combining continuation and sufficient
amount of refills of medication.8 Our findings support
these conclusions, especially in multiple drug users,
since our MPRY measure addressed both aspects of
adherence and showed good performance (high AUCs)
for identifying suboptimal refill adherence despite the
fact that it focused only on prevalent users. The
sensitivity could be further improved by calculatingCopyright # 2008 John Wiley & Sons, Ltd.the MPRY also for initial users starting at the time of
their first prescription. In that case, either the follow-up
period must be extended to include a 1 year period or a
shorter follow-up period should be accepted. The
specificity could be improved by including the criteria
used in our visual assessment. However, this requires a
more complicated algorithm and additional data.
Previously, not much attention has been given to the
issue of calculating adherence in patients using
multiple drugs for the same indication. We tested
whether calculating adherence percentages on thera-
peutic level might provide better results than at drug
class level, as it takes switching between drug classes
into account. In our study, the numbers of patients
misclassified due to switches between drugs, however,
was much smaller than the number of cases missed
when looking at the aggregated therapeutic level. There-
fore, we conclude that assessments on therapeutic level
were not sufficiently comprehensive in this case.
Several limitations of this study should be recog-
nized. First, when using prescription refill data one
does not measure true adherence behaviour, since not
all prescribed medication will be actually taken by the
patients. This is a widely known problem using
prescription refill data, and results in an overestimation
of actual adherence for all tested measures. In
particular, we used prescription and not dispensing
data, which are more susceptible to overestimation.
Furthermore, the reference method assessment was
performed visually by a single investigator. To avoid
misclassification bias, however, a strict stepwise
procedure was used with explicit assessment criteria.
Conclusions and recommendations
Differences between adherence measures were small
and favoured calculation on drug class level. ForPharmacoepidemiology and Drug Safety, 2009; 18: 159–165
DOI: 10.1002/pds
KEY POINTS
 Both the MPR and GAP are good measures for
identifying medication refill adherence in patients
using multiple drugs.
 Calculation of medication refill adherence on drug
class level is better than on indication level to deal with
possible switches among drugs.
comparing measures for medication refill adherence 165multiple drug use, both MPRY and GAP were good
measures for identifying suboptimal medication refill
adherence. MPRY is a simple measure, which could be
improved by including patient receiving an initial refill
during the study period. Because of the simplicity of
calculation, we recommend the MPRY for assessing
refill adherence in patients on a multiple drug regimen.ACKNOWLEDGEMENTS
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